TBXA2R

Thromboxane A2 receptor · P21731 · TBXA2R on Sugi Atlas →

302,736 patent compounds predicted against TBXA2R, 225,288 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ridogrel (SCHEMBL11708)	1.00	19/20
Ridogrel (SCHEMBL11709)	1.00	19/20
Ridogrel (SCHEMBL11710)	1.00	19/20
Ifetroban (SCHEMBL28135)	1.00	19/20
Bms-180291 (SCHEMBL28136)	1.00	19/20
Bms-180291 (SCHEMBL28137)	1.00	19/20
Vapiprost (SCHEMBL28550)	1.00	19/20
Vapiprost (SCHEMBL28551)	1.00	19/20
Iloprost (SCHEMBL4357)	0.45	12/20
SCHEMBL4358	0.40	12/20
Ramatroban (SCHEMBL29030)	1.00	8/20
Ramatroban (SCHEMBL29031)	1.00	8/20
SCHEMBL34165	0.65	6/20
Trimipramine (SCHEMBL35144)	1.00	4/20
Rifamycin (SCHEMBL2320)	1.00	3/20
Simvastatin (SCHEMBL2471)	1.00	3/20
Simvastatin (SCHEMBL2472)	1.00	3/20
Daunorubicin (SCHEMBL3041)	1.00	3/20
Doxorubicin (SCHEMBL3243)	1.00	3/20
Epirubicin (SCHEMBL8582)	1.00	3/20

Clinical trials — most relevant to TBXA2R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Thromboxane Function in Women With Endometriosis	PHASE4	RECRUITING
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study	PHASE4	COMPLETED
Vorapaxar on Thrombin Generation and Coagulability	PHASE4	COMPLETED
Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes	PHASE4	UNKNOWN
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation	PHASE4	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty	PHASE2/PHASE3	COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages	PHASE2/PHASE3	UNKNOWN
Thromboxane Receptor Antagonist to Improve Endothelial Function	PHASE2	COMPLETED
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo	PHASE2	UNKNOWN
Assessment of Therapeutic Effect of Rectal Vs. Intravenous Paracetamol in The Treatment of Patent Ductus Arteriosus (PDA) in Neonates	PHASE1/PHASE2	UNKNOWN
Defibrotide in COVID-19 Pneumonia	PHASE2	COMPLETED
DHA For The Treatment of Pediatric Concussion Related to Sports Injury	PHASE1	COMPLETED
Aspirin Resistance in Coronary Artery Disease	EARLY_PHASE1	COMPLETED
Platelets Function and Cardiovascular Events in Patients With End Stage Renal Disease	nan	UNKNOWN
Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes	nan	COMPLETED
Thrombin Regulated Platelet Activation	nan	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Positron Emission Tomography (PET) to Study Brain Signaling	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Sexual Hormones and Haemostasis: Observations for Women Health	nan	UNKNOWN
Genetic Influences of Albuterol Response In Children With Bronchiolitis	nan	COMPLETED
Comparison of Effects of Buffered and Enteric-coated Forms of Aspirin on Platelet Aggregation in Patients With Diabetes Mellitus and Chronic Coronary Syndrome	nan	COMPLETED
A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TBXA2R binder may also engage these)

Protein	Name	Similarity
P56486	—	1.000	P56486 →
P34978	—	1.000	P34978 →
P30987	—	0.999	P30987 →
Q95125	—	0.998	Q95125 →
O35932	—	0.985	O35932 →
PTGIR	Prostacyclin receptor	0.983	landscape →
P79393	—	0.982	P79393 →
Q9R261	—	0.982	Q9R261 →
A5D7K8	—	0.980	A5D7K8 →
PTGDR	Prostaglandin D2 receptor	0.978	landscape →
P70263	—	0.978	P70263 →
PTGER2	Prostaglandin E2 receptor EP2 subtype	0.977	landscape →
Q62928	—	0.975	Q62928 →
P43252	—	0.975	P43252 →
P43253	—	0.975	P43253 →
P70597	—	0.974	P70597 →
Q62053	—	0.974	Q62053 →
P30557	—	0.974	P30557 →
P35375	—	0.973	P35375 →
P34980	—	0.971	P34980 →
Q9XT82	—	0.966	Q9XT82 →
PTGER3	Prostaglandin E2 receptor EP3 subtype	0.966	landscape →
P50131	—	0.965	P50131 →
P46069	—	0.964	P46069 →
PTGER1	Prostaglandin E2 receptor EP1 subtype	0.959	landscape →
P47752	—	0.956	P47752 →
P43117	—	0.955	P43117 →
P34979	—	0.954	P34979 →
S1PR2	Sphingosine 1-phosphate receptor 2	0.953	landscape →
CNR2	Cannabinoid receptor 2	0.953	landscape →